Paul Reider
Corporate Officer/Principal bei COHERUS BIOSCIENCES, INC.
Vermögen: 194 252 $ am 31.03.2024
Profil
Paul Reider is a member of the Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc. He is also the Chief Commercial Officer at Coherus BioSciences, Inc. starting in 2022.
Previously, he worked as the Vice President of Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021.
He also held a position as the General Manager at Ipsen Biopharmaceuticals Canada, Inc. Mr. Reider completed his undergraduate degree and MBA at Bowling Green State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.04.2024 | 81 277 ( 0,07% ) | 194 252 $ | 31.03.2024 |
Aktive Positionen von Paul Reider
| Unternehmen | Position | Beginn |
|---|---|---|
| COHERUS BIOSCIENCES, INC. | Corporate Officer/Principal | 01.01.2021 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Paul Reider
| Unternehmen | Position | Ende |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Sales & Marketing | 01.01.2021 |
| Ipsen Biopharmaceuticals Canada, Inc. | Corporate Officer/Principal | - |
Ausbildung von Paul Reider
| Bowling Green State University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
| Ipsen Biopharmaceuticals Canada, Inc. |
